Bank of America Securities Analyst Reiterates Buy Rating on Novo Nordisk A/S, NVO Stock

Alert on NVO: The scanners at HealthTechMovers.com, with the help of Tipranks.com, found the following stock rating has recently occurred regarding this top healthtech stock. HealthTechMovers.com keeps investors informed of trending healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more.

Sachin Jain analyst at Bank of America Securities reiterates coverage on Novo Nordisk A/S (NVO) stock in the Healthcare sector with a Buy rating. TipRanks.com has Jain rated as a 4.4 star analyst with a 67% return on investment and a 11.6% success rate. Jain has not provided a price target.

TipRanks.com reports that Novo Nordisk A/S stock currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target for NVO's stock is $159.67. The target pricing ranges from a high forecast of $163 down to a low forecast of $156. Novo Nordisk A/S (NVO)’s stock last closing price was $142.50 which would put the average price target at 12.05% upside.

In addition, TradingView issued a rating for NVO's stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on NVO stock.